Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Lexeo Therapeutics (Nasdaq: LXEO), a clinical stage genetic medicine company, has announced its participation in several upcoming investor conferences. The company, which focuses on developing treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, will be presenting at four major healthcare and investment events in September and October 2024:

• H.C. Wainwright 26th Annual Global Investment Conference on September 9
• Baird 2024 Global Healthcare Conference on September 10
• Cantor 2024 Global Healthcare Conference on September 18
• Chardan's 8th Annual Genetic Medicines Conference on October 1

All presentations will be webcast live and available for replay on the company's website under the Investors section.

News Market Reaction – LXEO

+1.79%

1 alert

+1.79% News Effect

On the day this news was published, LXEO gained 1.79%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:

	H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET
	Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 1:25 PM ET
	Cantor 2024 Global Healthcare Conference on Wednesday, September 18, 2024 at 11:30 AM ET
	Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:30 PM ET

The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.

Media Response:
media@lexeotx.com

Investor Response:
Stephen Jasper
(858) 525-2047
stephen@gilmartinir.com

FAQ

What investor conferences will Lexeo Therapeutics (LXEO) attend in September and October 2024?

Lexeo Therapeutics will participate in four investor conferences: H.C. Wainwright Global Investment Conference (Sept. 9), Baird Global Healthcare Conference (Sept. 10), Cantor Global Healthcare Conference (Sept. 18), and Chardan's Genetic Medicines Conference (Oct. 1).

How can investors access Lexeo Therapeutics' (LXEO) conference presentations?

Investors can access live webcasts of Lexeo Therapeutics' presentations under the News & Events tab in the Investors section of the company's website. Replays will also be available after the events.

What are the main focus areas of Lexeo Therapeutics (LXEO)?

Lexeo Therapeutics is focused on developing treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease.

When is Lexeo Therapeutics (LXEO) presenting at the Chardan's Genetic Medicines Conference in 2024?

Lexeo Therapeutics is scheduled to present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:30 PM ET.